Attoriley Docket: 037003-0276603 Client Reference: 1995-30-0233D2 A Jun

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

ANDERSON et al.

Patent No.: 6,893,638 Application No.: 09/758,173

Issued: May 17, 2005 Filed: January 12, 2001

Title: METHODS FOR TREATING B CELL LYMPHOMA USING CD80-SPECIFIC

ANTIBODIES

<u>PETITION PURSUANT TO 37 C.F.R. §1.183 AND REQUEST FOR</u> <u>CERTIFICATE OF CORRECTION</u>

Office of Petitions Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

06/10/2005 SZEUDIE1 00000035 033975 6893638

01 FC:1811 100.00 DA 02 FC:1462 400.00 DA

Sir:

The patentees respectively request that the present petition be granted for the identification of the assignee's name in connection with the above-identified patent, wherein the omission of the assignee's name on the Form PTOL-85B was an inadvertent error. Pursuant to 37 C.F.R. §1.183 and 1.323, the patentees have enclosed herewith the fees required by 37 C.F.R. §1.17(h) (\$130.00) and 1.20(a) (\$100.00).

The patentees request that 37 C.F.R. §3.81(a) be waived for the inclusion of the assignee's name after the issuance of the patent. The present patent is a divisional of U.S. Patent Appl. No. 08/487,550, which was assigned from the inventors to IDEC Pharmaceuticals Corporation, as recorded on May 23, 1996, at Reel No. 7832/Frame No. 0646 (seeAppendix A) Further, a change of name from IDEC Pharmaceuticals Corporation to Biogen IDEC Inc. was recorded on August 6, 2004, at Reel No. 015044/Frame No. 0873 (see Appendix B) Both assignments were submitted for recordation with USPTO before the time of issuance.

In view of the foregoing, the patentees submit herewith a Certificate of Correction Form PTO-1050 to indicate that, at the time of issuance, U.S. Patent No. 6,893,638 was assigned to Biogen IDEC Inc.

This Certificate of Correction is also necessary due to USPTO omission of updated priority information in the section entitled "Related U.S. Application Data" and an entry of erroneous SEQ ID NOs. in claims 1 and 3. Specifically, an amendment pursuant to 37 C.F.R. § 1.312 was submitted on September 29, 2004 updating the status of related U.S. Patent Appl.

The PTO did not receive the following listed item(s) The FER Control of Cabo 20.

Attorney Docket: 037003-0276603 Client Reference: 1995-30-0233D2

No. 09/383,916. This amendment was acknowledged and entered by the examiner in a communication dated February 24, 2005. Upon reviewing the printed patent, the patentees discovered a U.S. Patent Office generated typographic error in claims 1 and 3. The phrase "SEQ ID NOs 5-6 and 7-3" should read "SEQ ID NOs 5-6 and 7-8" in claims 1 and 3. The correct language (SEQ ID NOS: 5-6 and 7-8 was present throughout prosecution of the application prior to the issuance of the patent. Even though these errors were generated by the Patent Office, the inadvertent error regarding the assignee's name (as discussed above) requires payment of the certificate of correction fee under 37 C.F.R. § 1.120(a).

Although the patentees believe additional fees (beyond the amount presented herein) are not necessary for consideration of this petition and entry of the certificate of correction as requested, should the patent office determine additional fees are due, the commissioner is authorized to charge such fees to the Deposit Account No. 03-3975.

Respectfully submitted,

THOMAS A. CAWLEY, JR., Ph.D.

LA Coul 7

Reg. No. 40944

Tel. No. (703) 905-2144 Fax No. (703) 905-2500

PILLSBURY WINTHROP SHAW PITTMAN LLP P.O. Box 10500 McLean, VA 22102 June 9, 2005

TAC/PAJ/YMD





UNITED STATES DEPARTMENT OF COMMERCE **Patent and Trademark Office**

ASSISTANT SECRETARY AND COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

MAY 29, 1996

PTAS

BURNS, DOANE, SWECKER & MATHIS, LLP ROBIN L. TESKIN, ESQ. POST OFFICE BOX 1404 ALEXANDRIA, VA 22313-1404



UNITED STATES PATENT AND TRADEMARK OFFICE NOTICE OF RECORDATION OF ASSIGNMENT DOCUMENT

THE ENCLOSED DOCUMENT HAS BEEN RECORDED BY THE ASSIGNMENT DIVISION OF THE U.S. PATENT AND TRADEMARK OFFICE. A COMPLETE MICROFILM COPY IS AVAILABLE AT THE ASSIGNMENT SEARCH ROOM ON THE REEL AND FRAME NUMBER REFERENCED BELOW.

PLEASE REVIEW ALL INFORMATION CONTAINED ON THIS NOTICE. THE INFORMATION CONTAINED ON THIS RECORDATION NOTICE REFLECTS THE DATA PRESENT IN THE PATENT AND TRADEMARK ASSIGNMENT SYSTEM. IF YOU SHOULD FIND ANY ERRORS OR HAVE QUESTIONS CONCERNING THIS NOTICE, YOU MAY CONTACT THE EMPLOYEE WHOSE NAME APPEARS ON THIS NOTICE AT 703-308-9723. PLEASE SEND REQUEST FOR CORRECTION TO: U.S. PATENT AND TRADEMARK OFFICE, ASSIGNMENT DIVISION, BOX ASSIGNMENTS, NORTH TOWER BUILDING, SUITE 10C35, WASHINGTON, D.C. 20231.

RECORDATION DATE: 05/23/1996

REEL/FRAME: 7832/0646

NUMBER OF PAGES: 3

BRIEF: ASSIGNMENT OF ASSIGNOR'S INTEREST (SEE DOCUMENT FOR DETAILS).

ASSIGNOR:

ANDERSON, DARRELL R.

DOC DATE: 11/13/1995

ASSIGNOR:

BRAMS, PETER

DOC DATE: 11/13/1995

ASSIGNOR:

HANNA, NABIL

DOC DATE: 11/13/1995

ASSIGNOR:

SHESTOWSKY, WILLIAM S.

DOC DATE: 11/14/1995

ASSIGNEE:

IDEC PHARMACEUTICALS CORPORATION 11011 TORREYANA ROAD SAN DIEGO, CALIFORNIA 92121

SERIAL NUMBER: 08487550

PATENT NUMBER:

FILING DATE: 06/07/1995

ISSUE DATE:



7832/0646 PAGE 2

JACQUELINE MOORE, EXAMINER ASSIGNMENT DIVISION OFFICE OF PUBLIC RECORDS

0127	12-131	
Attorney's	Docket	No.

ASSIGNMENT

(JOINT)

THIS ASSIGNMENT, by <u>DARRELL R. ANDERSON</u>, <u>PETER BRAMS</u>, <u>NABIL HANNA</u> and <u>BILL SHESTOWSKY</u> (hereinafter referred to as "the Assignors"), residing at <u>1851 NAVAJO PLACE</u>, <u>ESCONDIDO</u>, CA 92029; 4260 3RD AVENUE, #101, SAN DIEGO, CA 92103; 3255 FORTUNA RANCH ROAD, <u>OLIVENHAIN</u>, CA 92024; 1155 THOMAS AVENUE, SAN DIEGO, CA 92109; 4311 ROBBINS STREET, <u>SAN DIEGO</u>, CA 92122; and <u>1225 VIA MONTORO</u>, <u>ENCINITAS</u>, CA 92024, respectively, witnesseth:

WHEREAS, the Assignors have invented certain new and useful improvements in MONKEY MONOCLONAL ANTIBODIES SPECIFIC TO HUMAN B7.1 AND/OR B7.2 PRIMATIZED FORMS THEREOF, PHARMACEUTICAL COMPOSITIONS CONTAINING, AND USE THEREOF AS IMMUNOSUPPRESSANTS set forth in an application for Letters Patent of the United States, [], having an oath or declaration executed on even date herewith; [X] bearing Application No. 08/487,550, and filed on JUNE 7, 1995; and

WHEREAS, <u>IDEC PHARMACEUTICALS CORPORATION</u>, a corporation duly organized under and pursuant to the laws of <u>CALIFORNIA</u> and having its principal place of business at <u>11011 TORREYANA ROAD</u>, <u>SAN DIEGO</u>, <u>CA 92121</u> (hereinafter referred to as "the Assignee"), is desirous of acquiring the entire right, title, and interest in and to said inventions and said application for Letters Patent of the United States, and in and to any Letters Patent or Patents, United States or foreign, to be obtained therefor and thereon.

NOW, THEREFORE, in consideration of One Dollar (\$1.00) and other good and sufficient consideration, the receipt of which is hereby acknowledged, the Assignors have sold, assigned, transferred, and set over, and by these presents do sell, assign, transfer, and set over, unto the Assignee, its successors, legal representatives, and assigns the entire right, title, and interest in and to the above-mentioned inventions, application for Letters Patent, and any and all Letters Patent or Patents of the United States of America and all foreign countries that may be granted therefor and thereon, and in and to any and all divisions, continuations, and continuations-in-part of said application, and reissues and extensions of said Letters Patent or Patents, and all rights under the International Convention for the Protection of Industrial Property, the same to be held and enjoyed by the Assignee, for its own use and behalf and the use and behalf of its successors, legal representatives, and assigns, to the full end of the term or terms for which Letters Patent or Patents may be granted as fully and entirely as the same would have been held and enjoyed by the Assignors had this sale and assignment not been made;

AND for the same consideration, the Assignors hereby covenant and agree to and with the Assignee, its successors, legal representatives, and assigns, that, at the time of execution and delivery of these presents, the Assignors are the sole and lawful owners of the entire right, title, and interest in and to the inventions and application for Letters Patent above-mentioned, and that the same are unencumbered, and that the Assignors have good and full right and lawful authority to sell and convey the same in the manner herein set forth;

AND for the same consideration, the Assignors hereby covenant and agree to and with the Assignee, its successors, legal representatives, and assigns that the Assignors will, whenever counsel of the Assignee, or the counsel of its successors, legal representatives, and assigns, shall advise that any proceeding in connection with said inventions or said application for Letters Patent, or any proceeding in connection with Letters Patent for said inventions in any country, including

Page 1 of 2

Application Serial No. <u>08/487,550</u> Attorney's Docket No. <u>012712-131</u>


interference proceedings, is lawful and desirable, or that any division, continuation, or continuation-in-part of any application for Letters Patent, or any reissue or extension of any Letters Patent to be obtained thereon, is lawful and desirable, sign all papers and documents, take all lawful oaths, and do all acts necessary or required to be done for the procurement, maintenance, enforcement, and defense of Letters Patent for said inventions, without charge to the Assignee, its successors, legal representatives, and assigns, but at the cost and expense of the Assignee, its successors, legal representatives, and assigns;

AND the Assignors hereby request the Commissioner of Patents to issue said Letters Patent of the United States to the Assignee as the Assignee of said inventions, the Letters Patent to be issued for the sole use and behalf of the Assignee, its successors, legal representatives, and assigns.

Date .	11/13/95	Name of Assignor	Darrell R. ANDERSON
Date .	11-13-95	Name of Assignor	Detura , Peter BRAMS
Date .	(1/13/7)	Name of Assignor	Nabil HANNA
Date .	11/14/95	Name of Assignor	William S. Shestorty
		•	Bill SHESTOWSKY

FORM PTO-1595 (Rev. 6/93)

05-23-1996



ARTMENT OF COMMERCE Patent and Trademark Office

: SHEET 100181709 Attorney's Docket No. 012712-131 To the Honorable Commissioner of Patents and Trademarks. Please record the attached original documents or copy thereof. 2. Name and address of receiving party(ies): 1. Name of conveying party(ies): Name: IDEC Pharmaceuticals Corporation (1)Darrell R. Anderson (2)Peter Brams Address: 11011 Torreyana Road (3)Nabil Hanna (4) William S. Shestowsky JUN 0 9 2005 San Diego, CA 92121 Additional name(s) of conveying party(ies) attached? [] Yes [X] No 3. Nature of conveyance: TRADEM Merger [X] Assignment [] Security Agreement Change of Name Additional name(s) & address(es) attached? [] Yes Other: _ Execution Date: (1) 11/13/95 (2) 11/13/95 (3) 11/13/95 (4) 11/14/95 4. Application number(s) or patent number(s): If this document is being filed together with a new application, the execution date of the application is: A. Patent Application No.(s) B. Patent No.(s) 08/487,550 Additional numbers attached? [] Yes [X] No 6. Total number of applications and patents involved: 1 5. Name and address of party to whom correspondence concerning document should be mailed: 620 GT 05/28/96 08487550 40.00 CK 012712-131 1 581 Name: Robin L. Teskin. Esq. 7. Total fee (37 CFR 3.41): \$40.00 Address: Burns, Doane, Swecker & Mathis, LLP [X] Enclosed Post Office Box 1404 [X] Authorized to be charged to deposit account, if necessary Alexandria, Virginia 22313-1404 8. Deposit account number: 02-4800 (Attach duplicate copy of this page if paying by deposit account) DO NOT USE THIS SPACE 9. Statement and signature. To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document. May 23, 1996 Robin L. Teskin Name of Person Signing Total number of pages including cover sheet, attachments, and document: 3

Mail documents to be recorded with required cover sheet information to:

Commissioner of Patents and Trademarks Box Assignments Washington, D.C. 20231





UNITED STATES PATENT AND TRADEMARK OFFICE

UNDER SECRETARY OF COMMERCE FOR INTELLECTUAL PROPERTY AND DIRECTOR OF THE UNITED STATES PATENT AND TRADEMARK OFFICE

SEPTEMBER 03, 2004

PTAS

PILLSBURY WINTHROP LLP THOMAS A. CAWLEY, JR. P.O. BOX 10500 INTELLECTUAL PROPERTY GROUP

MCLEAN, VA 22102

UNITED STATES PATENT AND TRADEMARK OFFICE NOTICE OF RECORDATION OF ASSIGNMENT DOCUMENT

THE ENCLOSED DOCUMENT HAS BEEN RECORDED BY THE ASSIGNMENT DIVISION OF THE U.S. PATENT AND TRADEMARK OFFICE. A COMPLETE MICROFILM COPY IS AVAILABLE AT THE ASSIGNMENT SEARCH ROOM ON THE REEL AND FRAME NUMBER REFERENCED BELOW.

PLEASE REVIEW ALL INFORMATION CONTAINED ON THIS NOTICE. INFORMATION CONTAINED ON THIS RECORDATION NOTICE REFLECTS THE DATA PRESENT IN THE PATENT AND TRADEMARK ASSIGNMENT SYSTEM. IF YOU SHOULD FIND ANY ERRORS OR HAVE QUESTIONS CONCERNING THIS NOTICE, YOU MAY CONTACT THE EMPLOYEE WHOSE NAME APPEARS ON THIS NOTICE AT 703-308-9723. PLEASE SEND REQUEST FOR CORRECTION TO: U.S. PATENT AND TRADEMARK OFFICE, ASSIGNMENT DIVISION, BOX ASSIGNMENTS, CG-4, 1213 JEFFERSON DAVIS HWY, SUITE 320, WASHINGTON, D.C. 20231.

RECORDATION DATE: 08/06/2004

REEL/FRAME: 015044/0873

NUMBER OF PAGES: 7

BRIEF: CHANGE OF NAME (SEE DOCUMENT FOR DETAILS).

ASSIGNOR:

IDEC PHARMACEUTICALS CORPORATION DOC DATE: 11/12/2003

ASSIGNEE:

BIOGEN IDEC INC. 3030 CALLAN ROAD

SAN DIEGO, CALIFORNIA 92121

SERIAL NUMBER: 07431426

FILING DATE: 11/03/1989

ISSUE DATE:

PATENT NUMBER:

TITLE: ANTI-IDIOTYPE ANTIBODIES TO HUMAN MELANOMA-ASSOCIATED PROTEOGLYCAN

ANTIGEN

SERIAL NUMBER: 07735064

FILING DATE: 07/25/1991

ISSUE DATE: PATENT NUMBER:

TITLE: CHIMERIC ANTIBODIES FOR HUMAN THERAPY

SERIAL NUMBER: 07735069 FILING DATE: 07/25/1991

PATENT NUMBER: ISSUE DATE: TITLE: INDUCTION OF CYTOTOXIC T-LYMPHOCYTE RESPONSES

SERIAL NUMBER: 07856281 FILING DATE: 03/23/1992

PATENT NUMBER: ISSUE DATE:

TITLE: CHIMERIC ANTIBODIES FOR HUMAN THERAPY

SERIAL NUMBER: 07912292 FILING DATE: 07/10/1992

PATENT NUMBER: ISSUE DATE: TITLE: RECOMBINANT ANTIBODIES FOR HUMAN THERAPY

SERIAL NUMBER: 07977691 FILING DATE: 11/13/1992

PATENT NUMBER: ISSUE DATE:

TITLE: IMPAIRED DOMINANT SELECTABLE MARKER SEQUENCE FOR ENHANCEMENT OF

EXPRESSION OF CO-LINKED GENE PRODUCT AND EXPRESSION VECTOR SYSTEMS

COMPRISING SAME

SERIAL NUMBER: 08476674 FILING DATE: 06/07/1995

PATENT NUMBER: ISSUE DATE: TITLE: INDUCTION OF CYTOTOXIC T-LYMPHOCYTE RESPONSES

SERIAL NUMBER: 08746361 FILING DATE: 11/08/1996

PATENT NUMBER: ISSUE DATE:

TITLE: IDENTIFICATION OF UNIQUE BINDING INTERACTIONS BETWEEN CERTAIN ANTIBODIES AND THE HUMAN B7.1 AND B7.2 CO-STIMULATORY ANTIGENS

SERIAL NUMBER: 08933359 FILING DATE: 09/18/1997

PATENT NUMBER: ISSUE DATE:

TITLE: SYNERGISTIC COMPOSITION AND METHODS FOR TREATINGNEOPLASTIC OR

CANCEROUS GROWTHS AND FOR RESTORING OR BOOSTING HEMATOPOIESIS

SERIAL NUMBER: 09082472 FILING DATE: 05/21/1998

PATENT NUMBER: ISSUE DATE:

TITLE: RECOMBINANT ANTIBODIES FOR HUMAN THERAPY

SERIAL NUMBER: 09149479 FILING DATE: 09/08/1998

PATENT NUMBER: ISSUE DATE:

TITLE: METHOD FOR PRODUCING HUMAN ANTIBODIES IN SCID MICE WHICH USES

DENDRITIC CELLS PULSED WITH ANTIGEN-ANTIBODY COMPLEXES AND ANTIGEN-

ANTIBODY COMPLEXES AS IMMUNIZING AGENTS

SERIAL NUMBER: 09615796 FILING DATE: 07/13/2000

PATENT NUMBER: ISSUE DATE:

TITLE: IMPAIRED DOMINANT SELECTABLE MARKER SEQUENCE AND INTRONIC INSERTION

STRATEGIES FOR ENHANCEMENT OF EXPRESSION OF GENE PRODUCT AND

EXPRESSION VECTOR SYSTEMS COMPRISING SAME

SERIAL NUMBER: 09834933 FILING DATE: 04/16/2001

PATENT NUMBER: - ISSUE DATE:----

TITLE: TREATMENT OF B CELL MALIGNANCIES USING ANTI-CD40L ANTIBODIES IN

COMBINATION WITH ANTI-CD20 ANTIBODIES AND/OR CHEMOTHERAPEUTICS AND

RADIOTHERAPY

SERIAL NUMBER: 09850165 FILING DATE: 05/08/2001

PATENT NUMBER: ISSUE DATE:

TITLE: RECOMBINANT ANTIBODIES FOR HUMAN THERAPY

SERIAL NUMBER: 09877065 FILING DATE: 06/11/2001

PATENT NUMBER: ISSUE DATE:

TITLE: NOVEL GENE TARGETS AND LIGANDS THAT BIND THERETO FOR TREATMENT AND

DIAGNOSIS OF OVARIAN CARCINOMAS

SERIAL NUMBER: 09971631 FILING DATE: 10/09/2001

PATENT NUMBER: . ISSUE DATE:

TITLE: IMPAIRED DOMINANT SELECTABLE MARKER SEQUENCE AND INTRONIC INSERTION

STRATEGIES FOR ENHANCEMENT OF EXPRESSION OF GENE PRODUCT AND

EXPRESSION VECTOR SYSTEMS COMPRISING SAME

SERIAL NUMBER: 60057831 FILING DATE: 09/08/1997

PATENT NUMBER: ISSUE DATE:

TITLE: METHOD FOR PRODUCING HUMAN ANTIBODIES IN SCID MICE WHICH USES

DENDRITIC CELLS PULSED WITH ANTIGEN-ANTIBODY COMPLEXES AND ANTIGEN-

ANTIBODY COMPLEXES AS IMMUNIZING AGENTS

SERIAL NUMBER: 60109607 FILING DATE: 11/23/1998

PATENT NUMBER: ISSUE DATE:

TITLE: TUMOR ANTIGEN-SPECIFIC ANTIBODY-GP39 CHIMERIC PROTEIN CONSTRUCTS

SERIAL NUMBER: 60134848 FILING DATE: 05/19/1999

PATENT NUMBER: ISSUE DATE:

TITLE: OVERCOMING BARRIERS TO ADENOVIRUS VECTOR-MEDIATED GENE THERAPY FOR

CYSTIC FIBROSIS

SERIAL NUMBER: 60148288 FILING DATE: 08/11/1999

PATENT NUMBER: ISSUE DATE:

TITLE: NEW CLINICAL PARAMETERS FOR DETERMINING HEMATOLOGIC TOXICITY PRIOR

TO RADIOIMMUNOTHERAPY

SERIAL NUMBER: 60185390 FILING DATE: 02/28/2000

PATENT NUMBER: ISSUE DATE:

TITLE: METHOD FOR PRAPARING ANTI-MIF ANTIBODIES

SERIAL NUMBER: 60189050 FILING DATE: 03/14/2000

PATENT NUMBER: ISSUE DATE:

TITLE: TWO MONOCLONAL ANTIBODIES THAT BIND PHOSPHATIDYL SERINE AND A

METHOD OF KILLING TUMOR CELLS

SERIAL NUMBER: 60193467 FILING DATE: 03/31/2000

PATENT NUMBER: ISSUE DATE:

TITLE: COMBINED USE OF ANTI-CYTOKINE ANTIBODIES AND ANTI-CD20 FOR THE

TREATMENT OF B-CELL LYMPHOMA

SERIAL NUMBER: 60199365 --- FILING DATE: 04/25/2000

PATENT NUMBER: ISSUE DATE:

TITLE: INTRATHECAL ADMINISTRATION OF RITUXIMAB FOR TREATMENT OF CENTRAL

NERVOUS SYSTEM LYMPHOMAS

SERIAL NUMBER: 60209584 FILING DATE: 06/06/2000

PATENT NUMBER: ISSUE DATE:

TITLE: NON-AGONISTRIC ANTIBODIES TO HUMAN GP39, COMPOSITIONS CONTAINING

AND THERAPEUTIC USE THEREOF

SERIAL NUMBER: 60210451 FILING DATE: 06/09/2000

PATENT NUMBER: ISSUE DATE:

TITLE: NOVEL GENE TARGETS AND LIGANDS THAT BIND THERETO FOR TREATMENT AND

DIAGNOSIS OF OVARIAN CARCINOMAS

SERIAL NUMBER: 60212668 FILING DATE: 06/20/2000

PATENT NUMBER: ISSUE DATE:

TITLE: TREATMENT OF B-CELL ASSOCIATED DISEASES SUCH AS MALIGNANCIES AND

AUTOMMUNE DISEASES USING ANTI-CD20 ANTIBODY/RADIOLABLED ANTI-CD22

ANTIBODY COMBINATION

SERIAL NUMBER: 60213252 FILING DATE: 06/22/2000

PATENT NUMBER: ISSUE DATE:

TITLE: BISPECIFIC FUSION PROTEIN AND METHOD OF USE FOR ENHANCING EFFECTOR

CELL KILLING OF TARGET CELLS

SERIAL NUMBER: 60217706 FILING DATE: 07/12/2000

PATENT NUMBER: ISSUE DATE:

TITLE: TREATMENT OF B CELL MALIGNANCIES USING ANTOI-CD40L ANTIBODIES IN

COMBINATION WITH ANTI-CD20 ANTIBODIES AND/OR CHEMTHERAPETICS AND

RADIOTHERAPY

SERIAL NUMBER: 60233607 FILING DATE: 09/18/2000

PATENT NUMBER: ISSUE DATE:

TITLE: COMBINATION THERAPY FOR TREATMENT OF AUTOIMMUNE DISEASES COMPRISING

CD40L ANTAGONIST AND ANTIBODIES TO B7,CD19,CD20,CD22,CD23

SERIAL NUMBER: 60233625 FILING DATE: 09/18/2000

PATENT NUMBER: ISSUE DATE:

TITLE: METHOD FOR PREPARING ANTI-MIF ANTIBODIES

SERIAL NUMBER: 60241022 FILING DATE: 10/20/2000

PATENT NUMBER: ISSUE DATE:

TITLE: VARIANT LGG3 RITUXAN AND THERAPEUTIC USE THEREOF

SERIAL NUMBER: 60257147 FILING DATE: 12/22/2000

PATENT NUMBER: ISSUE DATE:

TITLE: COMBINATION THERAPY FOR TREATMENT OF AUTOIMMUNE DISEASES USING B

CELL DEPLETING/IMMUNOREGULATORY ANTIBODY COMBINATION

SERIAL NUMBER: 60264318 FILING DATE: 01/29/2001

PATENT NUMBER: ISSUE DATE:

TITLE: MODIFIED ANTIBODIES AND METHODS OF USE

SERIAL NUMBER: 60280139- -- FILING DATE: 04/02/2001

PATENT NUMBER: ISSUE DATE:

TITLE: EXPRESSION OF GNTIII IN A RECOMBINANT ANTI-CD20 CHO PRODUCTION CELL

LINE: EXPRESSION OF ANTIBODIES WITH ALTERED GLYCOFORMS LEADS TO AN

INCREASE IN ADCC THROUGH HIGHER AFFINITY FOR FCYRIII

FILING DATE: 06/25/2001 SERIAL NUMBER: 60300063

ISSUE DATE: PATENT NUMBER:

TITLE: GENES CORRELATED TO OVARIAN CANCER AND THEIR USE IN DEVELOPING

NOVEL THERAPEUTICS

FILING DATE: 07/10/2001 SERIAL NUMBER: 60303813

ISSUE DATE: PATENT NUMBER:

TITLE: INHIBITION OF APOPTOSIS PROCESS AND IMPROVEMENT OF CELL PERFORMANCE

FILING DATE: 11/09/2001 SERIAL NUMBER: 60331187

PATENT NUMBER: ISSUE DATE:

TITLE: ANTI CD 80 AND RITUXIMAB COMBINATION THERAPY OF B-CELL LYMPHOMA

FILING DATE: 11/16/2001 SERIAL NUMBER: 60331481

ISSUE DATE: PATENT NUMBER:

TITLE: POLYCISTRONIC EXPRESSION OF ANTIBODIES

SERIAL NUMBER: 60341860 FILING DATE: 12/21/2001

ISSUE DATE: PATENT NUMBER:

TITLE: GENES CORRELATED TO OVARIAN CANCER AND THEIR USE IN DEVELOPING

NOVEL THERAPEUTICS

SERIAL NUMBER: 60357140 FILING DATE: 02/19/2002

ISSUE DATE: PATENT NUMBER:

TITLE: PROSTATE SPECIFIC GENES AND THE USE THEREOF IN DESIGN OR

THERAPEUTICS

SERIAL NUMBER: 60367727 FILING DATE: 03/28/2002

ISSUE DATE: PATENT NUMBER:

TITLE: NOVEL GENE TARGETS AND LIGANDS THAT BIND THERETO FOR TREATMENT AND

DIAGNOSIS OF COLON CARCINOMAS

SERIAL NUMBER: 60381328 FILING DATE: 05/20/2002

ISSUE DATE: PATENT NUMBER:

TITLE: NOVEL GENE TARGETS AND LIGANDS THAT BIND THERETO FOR TREATMENT AND

DIAGNOSIS OF COLON CARCINOMAS

FILING DATE: 06/10/2002 SERIAL NUMBER: 60386746

ISSUE DATE: PATENT NUMBER:

TITLE: GENES UPREGULATED IN BREAST CANCER AND USE THEREOF AS TARGETS FOR

NOVEL THERAPIES AND DIAGNOSTIC AGENTS

FILING DATE: 06/10/2002 SERIAL NUMBER: 60386747

ISSUE DATE: PATENT NUMBER:

TITLE: NOVEL GENE TARGETS AND LIGANDS THAT BIND THERETO FOR TREATMENT AND

DIAGNOSIS OF COLON CARCINOMAS

FILING DATE: 06/10/2002 SERIAL NUMBER: 60386748

ISSUE DATE: PATENT NUMBER:

TITLE: GENES-CORRELATED TO OVARIAN-CANCER- AND THEIR USE IN DEVELOPING-

NOVEL THERAPEUTICS

SERIAL NUMBER: 60386759 FILING DATE: 06/10/2002

PATENT NUMBER: ISSUE DATE:

TITLE: PROSTATE SPECIFIC GENES AND THE USE THEREOF IN DESIGN OF

THERAPEUTICS

SERIAL NUMBER: 60390191 FILING DATE: 06/21/2002

PATENT NUMBER: ISSUE DATE:

TITLE: BUFFERED FORMULATIONS FOR CONCENTRATING ANTIBODIES

SERIAL NUMBER: 60396082 FILING DATE: 07/17/2002

PATENT NUMBER: ISSUE DATE:

TITLE: PROSTATE SPECIFIC GENES AND THE USE THEREOF IN DESIGN OF

THERAPEUTICS

SERIAL NUMBER: 60396141 FILING DATE: 07/17/2002

PATENT NUMBER: ISSUE DATE:

TITLE: GENES CORRELATED TO OVARIAN CANCER AND THEIR USE IN DEVELOPING

NOVEL THERAPEUTICS

SERIAL NUMBER: 60396255 FILING DATE: 07/17/2002

PATENT NUMBER: ISSUE DATE:

TITLE: GENES UPREGULATED IN BREAST CANCER

SERIAL NUMBER: 60400687 FILING DATE: 08/05/2002

PATENT NUMBER: ISSUE DATE:

TITLE: POLYCISTRONIC EXPRESSION OF ANTIBODIES

SERIAL NUMBER: 60405318 FILING DATE: 08/23/2002

PATENT NUMBER: ISSUE DATE:

TITLE: GENES UPREGULATED IN BREAST CANCER

SERIAL NUMBER: 60405319 FILING DATE: 08/23/2002

PATENT NUMBER: ISSUE DATE:

TITLE: GENES CORRELATED TO OVARIAN CANCER AND THEIR USE IN DEVELOPING

NOVEL THERAPEUTICS

SERIAL NUMBER: 60410506 FILING DATE: 09/13/2002

PATENT NUMBER: ISSUE DATE:

TITLE: METHOD OF PURIFYING ANTIBODIES BY SIMULATED MOVING BED

CHROMATOGRAPHY

SERIAL NUMBER: 60427564 FILING DATE: 11/20/2002

PATENT NUMBER: ISSUE DATE:

TITLE: NOVEL GENE TARGETS AND LIGANDS THAT BIND THERETO FOR TREATMENT AND

DIAGNOSIS OF COLON CARCINOMAS

SERIAL NUMBER: 60428274 FILING DATE: 11/22/2002

PATENT NUMBER: ISSUE DATE:

TITLE: GENES CORRELATED TO OVARIAN CANCER AND THEIR USE IN DEVELOPING

NOVEL-THERAPEUTICS-----

SERIAL NUMBER: 60452928 FILING DATE: 03/10/2003

PATENT NUMBER: ISSUE DATE:

TITLE: THIOL-MEDIATED DRUG ATTACHMENT TO TARGETING PEPTIDES

FILING DATE: 01/28/1999 SERIAL NUMBER: 09238741

ISSUE DATE: PATENT NUMBER:

TITLE: PRODUCTION OF TETRAVALENT ANTIBODIES

FILING DATE: 03/01/1999 SERIAL NUMBER: 09259337

PATENT NUMBER: ISSUE DATE:

TITLE: RADIOLABELING KIT AND BINDING ASSAY

SERIAL NUMBER: 09259338 FILING DATE: 03/01/1999

PATENT NUMBER: ISSUE DATE: TITLE: KIT FOR RADIOLABELING LIGANDS WITH YTTRIUM-90

SERIAL NUMBER: 09435992 FILING DATE: 11/08/1999

ISSUE DATE: PATENT NUMBER:

TITLE: TREATMENT OF B CELL MALIGNANCIES USING ANTI-CD40L ANTIBODIES IN COMBINATION WITH ANTI-CD20 ANTIBODIES AND/OR CHEMOTHERAPEUTICS AND

RADIOTHERAPY

SERIAL NUMBER: 09447594 FILING DATE: 11/23/1999

PATENT NUMBER: ISSUE DATE:

TITLE: TUMOR ANTIGEN-SPECIFIC ANTIBODY-GP39 CHIMERIC PROTEIN CONSTRUCTS

SERIAL NUMBER: 09576424 FILING DATE: 05/22/2000

ISSUE DATE: PATENT NUMBER:

TITLE: TREATMENT OF CROHN'SDISEASE USING ANTI-CD80 ANTIBODIES THAT DO NOT

INHIBIT THE BINDING OF CD80 ANTIGENTO CTLA-4

SERIAL NUMBER: 09612914 FILING DATE: 07/10/2000

PATENT NUMBER: ISSUE DATE:

TITLE: RECOMBINANT ANTI-CD4 ANTIBODIES FOR HUMAN THERAPY

SERIAL NUMBER: 09628186 FILING DATE: 07/28/2000

PATENT NUMBER: ISSUE DATE: TITLE: KIT FOR RADIOLABELING LIGANDS WITH YTTRIUM-90

SERIAL NUMBER: 09635929 FILING DATE: 08/10/2000

PATENT NUMBER: ISSUE DATE:

TITLE: TREATMEANT OF PATIENTS HAVING NON-HODGKINS LYMPHOMA WITH BONE

MARROW INVOLVEMENT WITH ANTI-CD20 ANTIBODIES

SERIAL NUMBER: 09758173 FILING DATE: 01/12/2001

ISSUE DATE: PATENT NUMBER:

TITLE: METHODS FOR TREATING B CELL LYMPHONA USING CD80-SPECIFIC ANTIBODIES

SERIAL NUMBER: 09772938 FILING DATE: 01/31/2001

PATENT NUMBER: ISSUE DATE:

TITLE: TREATMENT OF CELL MALIGNANCIES USING COMBINATION OF B CELL DEPLETING ANTIBODY AND IMMUNE MODULATING ANTIBODY RELATED

APPLICATIONS

FILING DATE: 02/26/2001

SERIAL NUMBER: 09791551

ISSUE DATE: PATENT NUMBER: TITLE: METHOD FOR PREPARING ANTI-MIF ANTIBODIES

SERIAL NUMBER: 09798525 FILING DATE: 02/21/2001

PATENT NUMBER: ISSUE DATE:

TITLE: METHOD FOR PRODUCING HUMAN ANTIBODIES IN SCID MICE WHICH USES

DENDRITIC CELLS PULSED WITH ANTIGEN-ANTIBODY COMPLEXES AND ANTIGEN-

ANTIBODY COMPLEXES AS IMMUNIZING AGENTS

SERIAL NUMBER: 09805217 FILING DATE: 03/14/2001

PATENT NUMBER: ISSUE DATE:

TITLE: ANTIBODIES THAT BIND PHOSPHATIDYL SERINE AND A METHOD OF THEIR USE

SERIAL NUMBER: 09822672 FILING DATE: 04/02/2001

PATENT NUMBER: ISSUE DATE:

TITLE: COMBINED USE OF ANTI-CYTOKINE ANTIBODIES OR ANTAGONISTS AND ANTI-

CD20 FOR TREATMENT OF B CELL LYMPHOMA

SERIAL NUMBER: 09840872 FILING DATE: 04/25/2001

PATENT NUMBER: ISSUE DATE:

TITLE: INTRATHECAL ADMINISTRATION OF RITUXIMAB FOR TREATMENT OF CENTRAL

NERVOUS SYSTEM LYMPHOMAS

SERIAL NUMBER: 09853580 FILING DATE: 05/14/2001

PATENT NUMBER: ISSUE DATE:

TITLE: SYNERGISTIC COMPOSITION AND METHODS FOR TREATING NEOPLASTIC OR

CANCEROUS GROWTHS AND FOR RESTORING OR BOOSTING HEMATOPOIESIS

SERIAL NUMBER: 09853581 FILING DATE: 05/14/2001

PATENT NUMBER: ISSUE DATE:

TITLE: SYNERGISTIC COMPOSITION AND METHODS FOR TREATING NEOPLASTIC OR

CANCEROUS GROWTHS AND FOR RESTORING OR BOOSTING HEMATOPOIESIS

SERIAL NUMBER: 09855717 FILING DATE: 05/16/2001

PATENT NUMBER: ISSUE DATE:

TITLE: TREATMENT OF B CELL MALIGNANCIES USING COMBINATION OF B CELL

DEPLETING ANTIBODY AND IMMUNE MODULATING ANTIBODY RELATED

APPLICATIONS

SERIAL NUMBER: 09856534 FILING DATE: 09/04/2001

PATENT NUMBER: ISSUE DATE:

TITLE: TUMOR ANTIGEN- SPECIFIC ANTIBODY- GP39 CHIMERIC PROTEIN CONSTRUCTS

SERIAL NUMBER: 09874141 FILING DATE: 06/06/2001

PATENT NUMBER: ISSUE DATE:

TITLE: NON-AGONISTIC ANTIBODIES TO HUMAN GP39, COMPOSITIONS CONTAINING,

AND THERAPEUTIC USE THEREOF

SERIAL NUMBER: 09883962 FILING DATE: 06/20/2001

PATENT NUMBER: ISSUE DATE:

TITLE: TREATMENT OF B-CELL ASSOCIATED DISEASES SUCH AS MALIGNANCES AND

AUTOIMMUNE DISEASES USING A COLD ANTI-CD20 ANTIBODY/RADIOLABELED

ANTI-CD22 ANTIBODY COMBINATION

SERIAL NUMBER: 09954274 FILING DATE: 09/18/2001

PATENT NUMBER: ISSUE DATE:

TITLE: COMBINATION THERAPY FOR TREATMENT OF AUTOIMMUNE DISEASES USING B

CELL DEPLETING/IMMUNOREGULATORY ANTIBODY COMBINATION

SERIAL NUMBER: 09982849 FILING DATE: 10/22/2001

PATENT NUMBER: ISSUE DATE: TITLE: VARIANT IGG3 RITUXAN AND THERAPEUTIC USE THEREOF

SERIAL NUMBER: 09985646 FILING DATE: 11/05/2001

PATENT NUMBER: ISSUE DATE:

TITLE: USE OF CD23 ANTAGONISTS FOR THE TREATMENT OF NEOPLASTIC DISORDERS

SERIAL NUMBER: 09986174 FILING DATE: 11/07/2001

PATENT NUMBER: ISSUE DATE:

TITLE: BISPECIFIC FUSION PROTEIN AND METHOD OF USE FOR ENHANCING EFFECTOR

CELL KILLING OF TARGET CELLS

SERIAL NUMBER: 10058120 FILING DATE: 01/29/2002

PATENT NUMBER: ISSUE DATE:

TITLE: MODIFIED ANTIBODIES AND METHODS OF USE

SERIAL NUMBER: 10073138 FILING DATE: 02/13/2002

PATENT NUMBER: ISSUE DATE:

TITLE: IDENTIFICATION OF UNIQUE BINDING INTERACTIONS BETWEEN CERTAIN ANTIBODIES AND THE HUMAN B7.1 AND B7.2 CO-STIMULATORY ANTIGENS

SERIAL NUMBER: 10096963 FILING DATE: 03/14/2002

PATENT NUMBER: ISSUE DATE:

TITLE: TREATMENT OF B CELL MALIGNANCIES USING ANTI-CD40L ANTIBODIES IN COMBINATION WITH ANTI-CD20 ANTIBODIES AND/OR CHEMOTHERAPEUTICS AND

RADIOTHERAPY

SERIAL NUMBER: 10109853 FILING DATE: 04/01/2002

PATENT NUMBER: ISSUE DATE:

TITLE: NOVEL METHOD FOR INTEGRATING GENES AT SPECIFIC SITES IN MAMMALIAN

CELLS VIA HOMOLOGOUS RECOMBINATION AND VECTORS FOR ACCOMPLISHING THE SAME

SERIAL NUMBER: 10113929 FILING DATE: 04/02/2002

PATENT NUMBER: ISSUE DATE: TITLE: RECOMBINANT ANTIBODIES COEXPRESSED WITH GNTIII

SERIAL NUMBER: 10171680 FILING DATE: 06/17/2002

PATENT NUMBER: ISSUE DATE:

TITLE: HUMANIZED ANTIBODIES TO HUMAN GP39, COMPOSITIONS CONTAINING AND

THERAPEUTIC USE THEREOF

SERIAL NUMBER: 10171681 FILING DATE: 06/17/2002

TITLE: TREATING AUTOIMMUNE DISEASES WITH HUMANIZED ANTI-CD40L ANTIBODY

FILING DATE: 07/10/2002 SERIAL NUMBER: 10191052

ISSUE DATE: PATENT NUMBER:

TITLE: INHIBITION OF APOPTOSIS PROCESS AND IMPROVEMENT OF CELL PERFORMANCE

SERIAL NUMBER: 10195426 FILING DATE: 07/16/2002

PATENT NUMBER: ISSUE DATE:

TITLE: NEW CLINICAL PARAMETERS FOR DETERIMING HEMATOLOGIC TOXICITY PRIOR

TO RADIOIMMUNOTHERAPY

SERIAL NUMBER: 10211357 FILING DATE: 08/05/2002

PATENT NUMBER: ISSUE DATE:

TITLE: RECOMBINANT ANTI-CD4 ANTIBODIES FOR HUMAN THERAPY

FILING DATE: 09/12/2002 SERIAL NUMBER: 10241832

PATENT NUMBER: ISSUE DATE:

TITLE: USE OF CD23 ANTAGONISTS FOR THE TREATMENT OF NEOPLASTIC DISORDERS

SERIAL NUMBER: 10241836 FILING DATE: 09/12/2002

PATENT NUMBER: ISSUE DATE: TITLE: IMMUNOREGULATORY ANTIBODIES AND USES THEREOF

SERIAL NUMBER: 10291532 FILING DATE: 11/12/2002

PATENT NUMBER: ISSUE DATE:

TITLE: ANTI-CD80 ANTIBODY HAVING ADCC ACTIVITY FOR ADCC MEDIATED KILLING

OF B CELL LYMPHOMA CELLS ALONE OR IN COMBINATION WITH OTHER

THERAPIES

FILING DATE: 11/18/2002 SERIAL NUMBER: 10295823

ISSUE DATE: PATENT NUMBER:

TITLE: POLYCISTRONIC EXPRESSION OF ANTIBODIES

FILING DATE: 12/23/2002 SERIAL NUMBER: 10326924

ISSUE DATE: PATENT NUMBER:

TITLE: GENES OVEREXPRESSED BY OVARIAN CANCER AND THEIR USE IN DEVELOPING

NOVEL THERAPEUTICS, ESPECIALLY ANTIBODIES

SERIAL NUMBER: 10367978 FILING DATE: 02/19/2003

ISSUE DATE: PATENT NUMBER:

TITLE: PROSTATE SPECIFIC GENES AND THE USE THEREOF IN DESIGN OR

THERAPEUTICS

SERIAL NUMBER: 10384356 FILING DATE: 03/10/2003

PATENT NUMBER: ISSUE DATE:

TITLE: NEUTRALIZING HIGH AFFINITY HUMAN MONOCLONAL ANTIBODIES SPECIFIC TO

RSV F-PROTEIN AND METHODS FOR THEIR MANUFACTURE AND THERAPEUTIC USE

THEREOF

SERIAL NUMBER: 10661086 FILING DATE: 09/12/2003

ISSUE DATE: PATENT NUMBER:

TITLE: METHOD-OF-PURIFYING POLYPEPTIDES-BY-SIMULATED-MOVING BED

CHROMATOGRAPHY

, . . .

SERIAL NUMBER: 10743398 FILING DATE: 12/23/2003

ISSUE DATE: PATENT NUMBER: TITLE: INDUCTION OF CYTOTOXIC T-LYMPHOCYTE RESPONSES

SERIAL NUMBER: 10743739 FILING DATE: 12/24/2003

ISSUE DATE: PATENT NUMBER:

TITLE: SYNERGISTIC COMPOSITION AND METHODS FOR TREATING NEOPLASTIC OR CANCEROUS GROWTHS AND FOR RESTORING OR BOOSTING HEMATOPOIESIS

FILING DATE: 08/11/1999 SERIAL NUMBER: 60148287

ISSUE DATE: PATENT NUMBER:

TITLE: TREATMENT OF PATIENTS HAVING NON-HODGKINS LYMPHOMA WITH BONE MARROW

INVOLVEMENT WITH ANTI-CD20 ANTIBODIES

SERIAL NUMBER: 60479910 FILING DATE: 06/20/2003

ISSUE DATE: PATENT NUMBER:

TITLE: USE OF DEPTH FILTRATION AND CONTINUOUS CENTRIFUGATION TO CLARIFY

CELL SAMPLES

SERIAL NUMBER: 60510552 FILING DATE: 10/14/2003

ISSUE DATE: PATENT NUMBER:

TITLE: LECTIN AFFINITY PURIFICATION AND IDENTIFICATION OF PROTEINS OF

VASCULAR TISSUE ASSOCIATED WITH A DISEASE OR DISORDER

FILING DATE: 11/10/2003 SERIAL NUMBER: 10703669

PATENT NUMBER: ISSUE DATE:

TITLE: TREATMENT OF B-CELL ASSOCIATED DISEASES SUCH AS MALIGNANCIES AND

AUTOIMMUNE DISEASES USING A COLD ANTI-CD20 ANTIBODY/RADIOLABELED

ANTI-CD22 ANTIBODY COMBINATION

SERIAL NUMBER: 10796158 FILING DATE: 03/10/2004

ISSUE DATE: PATENT NUMBER:

TITLE: THIOL-MEDIATED DRUG ATTACHMENT TO TARGETING PEPTIDES

SERIAL NUMBER: 10871261 FILING DATE: 06/21/2004

ISSUE DATE: PATENT NUMBER:

TITLE: USE OF DEPTH FILTRATION IN SERIES WITH CONTINUOUS CENTRIFUGATION TO

CLARIFY MAMMALIAN CELL CULTURES

SERIAL NUMBER: 10058069 FILING DATE: 01/29/2002

ISSUE DATE: PATENT NUMBER:

TITLE: ENGINEERED TETRAVALENT ANTIBODIES AND METHODS OF USE

SERIAL NUMBER: 07680808
PATENT NUMBER: 5270202 FILING DATE: 03/12/1991 ISSUE DATE: 12/14/1993

TITLE: ANTI-IDIOTYPE ANTIBODIES TO HUMAN MELANOMA-ASSOCIATED PROTEOGLYCAN

ANTIGEN

SERIAL NUMBER: 07919787 FILING DATE: 07/24/1992 - PATENT NUMBER: 5585103_____ ISSUE DATE: 12/17/1996____

TITLE: INDUCTION OF CYTOTOXIC T-LYMPHOCYTE RESPONSES

SERIAL NUMBER: 08147696 FILING DATE: 11/03/1993
PATENT NUMBER: 5648267 FILING DATE: 07/15/1997

TITLE: IMPAIRED DOMINANT SELECTABLE MARKER SEQUENCE AND INTRONIC INSERTION

STRATEGIES FOR ENHANCEMENT OF EXPRESSION OF GENE PRODUCT AND

EXPRESSION VECTOR SYSTEMS COMPRISING SAME

SERIAL NUMBER: 08379072 FILING DATE: 01/25/1995
PATENT NUMBER: 5658570 FILING DATE: 08/19/1997

TITLE: RECOMBINANT ANTIBODIES FOR HUMAN THERAPY

SERIAL NUMBER: 08478039 FILING DATE: 06/07/1995 PATENT NUMBER: 5681722 ISSUE DATE: 10/28/1997

TITLE: RECOMBINANT ANTIBODIES FOR HUMAN THERAPY

SERIAL NUMBER: 08481869 FILING DATE: 06/07/1995
PATENT NUMBER: 5693780 FILING DATE: 12/02/1997

TITLE: RECOMBINANT ANTIBODIES FOR HUMAN THERAPY

SERIAL NUMBER: 08472311 FILING DATE: 06/07/1995
PATENT NUMBER: 5695770 ISSUE DATE: 12/09/1997

TITLE: INDUCTION OF CYTOTOXIC T-LYMPHOCYTE RESPONSES

SERIAL NUMBER: 08351001 FILING DATE: 12/07/1994 PATENT NUMBER: 5709860 FILING DATE: 01/20/1998

TITLE: INDUCTION OF CYTOTOXIC T-LYMPHOCYTE RESPONSES

SERIAL NUMBER: 08484334 FILING DATE: 06/07/1995 PATENT NUMBER: 5733779 ISSUE DATE: 03/31/1998

TITLE: IMPAIRED DOMINANT SELECTABLE MARKER SEQUENCE AND INTRONIC INSERTION

STRATEGIES FOR ENHANCEMENT OF EXPRESSION OF GENE PRODUCT AND

EXPRESSION VECTOR SYSTEMS COMPRISING SAME

SERIAL NUMBER: 08476349 FILING DATE: 06/07/1995 PATENT NUMBER: 5750105 FILING DATE: 05/12/1998

TITLE: RECOMBINANT ANTIBODIES FOR HUMAN THERAPY

SERIAL NUMBER: 08476237 FILING DATE: 06/07/1995
PATENT NUMBER: 5756096 ISSUE DATE: 05/26/1998

TITLE: RECOMBINANT ANTIBODIES FOR HUMAN THERAPY

SERIAL NUMBER: 08488376 FILING DATE: 06/07/1995
PATENT NUMBER: 5811524 ISSUE DATE: 09/22/1998

TITLE: NEUTRALIZING HIGH AFFINITY HUMAN MONOCLONAL ANTIBODIES SPECIFIC TO RSV F-PROTEIN AND METHODS FOR THEIR MANUFACTURE AND THERAPEUTIC USE THEREOF

SERIAL NUMBER: 08819866 FILING DATE: 03/14/1997
PATENT NUMBER: 5830698 ISSUE DATE: 11/03/1998

TITLE: NOVEL METHOD FOR INTEGRATING GENES AT SPECIFIC SITES IN MAMMALIAN -- CELLS VIA HOMOLOGOUS RECOMBINATION AND VECTORS FOR ACCOMPLISHING

THE SAME

SERIAL NUMBER: 08634223 FILING DATE: 04/18/1996
PATENT NUMBER: 5840298 FILING DATE: 11/24/1998

TITLE: NEUTRALIZING HIGH AFFINITY HUMAN MONOCLONAL ANTIBODIES SPECIFIC TO RSV F-PROTEIN AND METHODS FOR THEIR MANUFACTURE AND THERAPEUTIC USE THEREOF

SERIAL NUMBER: 08634224 FILING DATE: 04/18/1996 PATENT NUMBER: 5866125 FILING DATE: 02/02/1999

TITLE: NEUTRALIZING HIGH AFFINITY HUMAN MONOCLONAL ANTIBODIES SPECIFIC TO RSV F-PROTEIN AND METHODS FOR THEIR MANUFACTURE AND THERAPEUTIC USE THEREOF

SERIAL NUMBER: 08634400 FILING DATE: 04/18/1996 PATENT NUMBER: 5939068 ISSUE DATE: 08/17/1999

TITLE: NEUTRALIZING HIGH AFFINITY HUMAN MONOCLONAL ANTIBODIES SPECIFIC TO RSV F-PROTEIN AND METHODS FOR THEIR MANUFACTURE AND THERAPEUTIC USE THEREOF

SERIAL NUMBER: 08635878 FILING DATE: 04/18/1996 PATENT NUMBER: 5955364 FILING DATE: 09/21/1999

TITLE: NEUTRALIZING HIGH AFFINITY HUMAN MONOCLONAL ANTIBODIES SPECIFIC TO RSV F-PROTEIN AND METHODS FOR THEIR MANUFACTURE AND THERAPEUTIC USE THEREOF

SERIAL NUMBER: 09023715 FILING DATE: 02/13/1998 PATENT NUMBER: 5998144 FILING DATE: 12/07/1999

TITLE: METHOD FOR INTEGRATING GENES AT SPECIFIC SITES IN MAMMALIAN CELLS VIA HOMOLOGOUS RECOMBINATION AND VECTORS FOR ACCOMPLISHING THE SAME

SERIAL NUMBER: 08554840 FILING DATE: 11/07/1995
PATENT NUMBER: 6001358 ISSUE DATE: 12/14/1999

TITLE: HUMANIZED ANTIBODIES TO HUMAN GP39, COMPOSITIONS CONTAINING AND THERAPEUTIC USE THEREOF

SERIAL NUMBER: 09013092 FILING DATE: 01/26/1998 PATENT NUMBER: 6017733 FILING DATE: 01/25/2000

TITLE: IMPAIRED DOMINANT SELECTABLE MARKER SEQUENCE AND INTRONIC INSERTION STRATEGIES FOR ENHANCEMENT OF EXPRESSION OF GENE PRODUCT AND EXPRESSION VECTOR SYSTEMS COMPRISING SAME

SERIAL NUMBER: 08487550 FILING DATE: 06/07/1995
PATENT NUMBER: 6113898 ISSUE DATE: 09/05/2000
TITLE: HUMAN B7.1-SPECIFIC PRIMATIZED ANTIBODIES AND TRANSFECTOMAS

TITLE: HUMAN B7.1-SPECIFIC PRIMATIZED ANTIBODIES AND TRANSFECTOMAS EXPRESSING SAID ANTIBODIES

SERIAL NUMBER: 08523894 FILING DATE: 09/06/1995 PATENT NUMBER: 6136310 ISSUE DATE: 10/24/2000

TITLE: RECOMBINANT ANTI-CD4 ANTIBODIES FOR HUMAN THERAPY

SERIAL NUMBER: -09280999 FILING DATE: 03/30/1999
PATENT NUMBER: 6159730 ISSUE DATE: 12/12/2000

TITLE: IMPAIRED DOMINANT SELECTABLE MARKER SEQUENCE AND INTRONIC INSERTION

STRATEGIES FOR ENHANCEMENT OF EXPRESSION OF GENE PRODUCT AND

EXPESSION VECTOR SYSTEMS COMPRISING SAME

 SERIAL NUMBER: 09024220
 FILING DATE: 02/17/1998

 PATENT NUMBER: 6197311
 ISSUE DATE: 03/06/2001

TITLE: INDUCTION OF CYTOTOXIC T-LYMPHOCYTE RESPONSES

FILING DATE: 03/03/1999 PATENT NUMBER: 6207858 SERIAL NUMBER: 09261207 ISSUE DATE: 03/27/2001

TITLE: REGIOSELECTIVE SYNTHESIS OF DTPA DERIVATIVES

SERIAL NUMBER: 08449728
PATENT NUMBER: 6270769 FILING DATE: 05/24/1995 ISSUE DATE: 08/07/2001

TITLE: INDUCTION OF CYTOTOXIC T-LYMPHOCYTE RESPONSES

SERIAL NUMBER: 09259347 FILING DATE: 03/01/1999 PATENT NUMBER: 6300143 ISSUE DATE: 10/09/2001 TITLE: ELECTROCHEMILUMINESCENT ASSAYS FOR EUKARYOTIC CELLS

SERIAL NUMBER: 09335697 FILING DATE: 06/18/1999 PATENT NUMBER: 6413771 ISSUE DATE: 07/02/2002

TITLE: NEUTRALIZING HIGH AFFINITY HUMAN MONOCLONAL ANTIBODIES SPECIFIC TO RSV F-PROTEIN AND METHODS FOR THEIR MANUFACTURE AND THERAPUTIC USE THEREOF

FILING DATE: 06/30/1999 SERIAL NUMBER: 09343485 ISSUE DATE: 07/02/2002 PATENT NUMBER: 6413777

TITLE: NOVEL METHOD FOR INTEGRATING GENES AT SPECIFIC SITES IN MAMMALIAN CELLS VIA HOMOLOGOUS RECOMBINATION AND VECTORS FOR ACCOMPLISHING THE SAME

SERIAL NUMBER: 08925339 FILING DATE: 09/08/1997 PATENT NUMBER: 6440418 ISSUE DATE: 08/27/2002 TITLE: METHODS OF TREATING AUTOIMMUNE DISEASES WITH GP39-SPECIFIC ANTIBODIES

FILING DATE: 07/26/2000 SERIAL NUMBER: 09625856 ISSUE DATE: 09/17/2002 PATENT NUMBER: 6451284

TITLE: NEW CLINICAL PARAMETERS FOR DETERMINING HEMATOLOGIC TOXICITY PRIOR TO RADIOIMMUNOTHERAPHY

SERIAL NUMBER: 09332595 FILING DATE: 06/14/1999 PATENT NUMBER: 6506383 FILING DATE: 01/14/2003

TITLE: HUMANIZED ANTIBODIES OF HUMAN GP39, COMPOSITIONS CONTAINING AND THERAPEUTIC USE THEREOF

SERIAL NUMBER: 09383916 FILING DATE: 08/26/1999 ISSUE DATE: 03/23/2004 PATENT NUMBER: 6709654 TITLE: TREATMENT OF PSORIASIS USING ANTI-B7.1(CD80) ANTIBODIES

SERIAL NUMBER: 09740003 FILING DATE: 12/20/2000 PATENT NUMBER: 6733763 ISSUE DATE: 05/11/2004

SHAREILL COLES, EXAMINER ASSIGNMENT DIVISION OFFICE OF PUBLIC RECORDS

BOX ASSIGNMENTS	7001061		DO NOT USE FO	OR TRADEMARKS
	RECORDATION FO PATENT APPLICATIO	NS & PATENTS ONLY		
TO THE DIRECTOR OF THE U	S PATENT AND TRADEMARK O	FFICE:		
SIR: PLEASE RECORD THE A	TACHED ORIGINAL DOCUMEN	115 OR COPT THERE	.or.	
1. NAME OF CONVEYING PAR	(TY(IES) (ASSIGNORS(S)):	2.		
1. Idec Pharmaceuticals Corpor	auon	4.		
3.		6.		
5.		8.		
7. ADDITIONAL NAME(S) OF CO	NVEYING PARTY(IES) ATTACHI			
2. PARTY(IES) (ASSIGNEE(S))	RECEIVING INTEREST:			
NAME: Biogen Idec Inc.				
ADDRESS: 3030 Callan Road,	San Diego, California 92121			
ADDITIONAL NAME(S) & ADDI	RESS(ES) ATTACHED? YES	⊠NO		
2 NATURE OF CONVEYANCE	F (DOCUMENT):			
	ocument for recordation—multiple	copies of same Assign	nment signed by differer	t inventors is one
document)		neor Even	DATE: 11/12/02	
☐ASSIGNMENT OF	WHOLE PART INTE	REST EXEC	. DATE: 11/12/03	
□ORIGINAL	FACSIMILE/PHOTOCOPY			
CHANGE OF NAME	VERIFIED TRANSLATION			
SECURITY MERGER	OTHER:	MITH MOTE IE DAT	ES ON DECLADATION	AND
EXECUTION DATE(S) ON THE	DECLARATION IF FILED HERE	WITH (NOTE: IF DAT	ES ON DECLARATION	AND
ASSIGNMENT DIFFER SEE ATTY!)				
ADDIOTIVE TO THE PAT NO	(O) OTHERS ON ADDITIONAL	CHEET(C) attached?	VIVES INO	
4.5 APPL. NO.(S) OR PAT NO.	(S). OTHERS ON ADDITIONAL	SHEET(S) attached?	⊠YES □NO	1st INVENTOR
4.5 APPL. NO.(S) OR PAT NO. A. PAT. APP. NO.(S) M#	(S). OTHERS ON ADDITIONAL 1st INVENTOR	B. PATENT NO(S)	M#	1# INVENTOR
4.5 APPL. NO.(S) OR PAT NO. A. PAT. APP. NO.(S) M# series code/serial no	(S). OTHERS ON ADDITIONAL 1st INVENTOR	B. PATENT NO(S)	M#	1# INVENTOR if not in item 1
4.5 APPL. NO.(S) OR PAT NO. A. PAT. APP. NO.(S) M# series code/serial no See Attached	(S). OTHERS ON ADDITIONAL 1st INVENTOR	B. PATENT NO(S) See Attached	M#	
4.5 APPL. NO.(S) OR PAT NO. A. PAT. APP. NO.(S) M# series code/serial no See Attached Appendix (4 pages)	(S). OTHERS ON ADDITIONAL 1st INVENTOR if not in item 1	See Attached Appendix	(M#. 47.4.	
4.5 APPL. NO.(S) OR PAT NO. A. PAT. APP. NO.(S) M# series code/serial no See Attached	(S). OTHERS ON ADDITIONAL 1st INVENTOR if not in item 1 Whom Correspondence	See Attached Appendix 6. NUMBER INVO	(M#. 47.4.	
4.5 APPL. NO.(S) OR PAT NO. A. PAT. APP. NO.(S) series code/serial no See Attached Appendix (4 pages) 5. Name & Address of Party to Concerning Document Show	(S). OTHERS ON ADDITIONAL 1st INVENTOR if not in item 1 Whom Correspondence	See Attached Appendix 6. NUMBER INVO	LVED: PATS <u>34</u> = TOTAL =	if not in item 1
4.5 APPL. NO.(S) OR PAT NO. A. PAT. APP. NO.(S) series code/serial no See Attached Appendix (4 pages) 5. Name & Address of Party to Concerning Document Should Pillsbury Winthrop LLP	(S). OTHERS ON ADDITIONAL 1st INVENTOR if not in item 1 Whom Correspondence	See Attached Appendix 6. NUMBER INVO APPLNS 112 +	LVED: PATS <u>34</u> = TOTAL = E DUE: (Code 8021)	if not in item 1
4.5 APPL. NO.(S) OR PAT NO. A. PAT. APP. NO.(S) series code/serial no See Attached Appendix (4 pages) 5. Name & Address of Party to Concerning Document Shou Pillsbury Winthrop LLP Intellectual Property Group	(S). OTHERS ON ADDITIONAL 1st INVENTOR if not in item 1 Whom Correspondence Id be Mailed:	See Attached Appendix 6. NUMBER INVO APPLNS 112 + 7. AMOUNT OF FE	LVED: PATS <u>34</u> = TOTAL = E DUE: (Code 8021)	if not in item 1
4.5 APPL. NO.(S) OR PAT NO. A. PAT. APP. NO.(S) series code/serial no See Attached Appendix (4 pages) 5. Name & Address of Party to Concerning Document Should Pillsbury Winthrop LLP	(S). OTHERS ON ADDITIONAL 1st INVENTOR if not in item 1 Whom Correspondence Id be Mailed:	See Attached Appendix 6. NUMBER INVO APPLNS 112 + 7. AMOUNT OF FE	LVED: PATS <u>34</u> = TOTAL = E DUE: (Code 8021)	if not in item 1
4.5 APPL. NO.(S) OR PAT NO. A. PAT. APP. NO.(S) series code/serial no See Attached Appendix (4 pages) 5. Name & Address of Party to Concerning Document Shou Pillsbury Winthrop LLP Intellectual Property Group	(S). OTHERS ON ADDITIONAL 1st INVENTOR if not in item 1 Whom Correspondence Id be Mailed:	B. PATENT NO(S) See Attached Appendix 6. NUMBER INVO APPLNS 112 + 7. AMOUNT OF FEI ABOVE TOTAL x	LVED: PATS <u>34</u> = TOTAL = E DUE: (Code 8021) \$40 = \$5840	<u>if not in item 1</u> <u>146</u>
4.5 APPL. NO.(S) OR PAT NO. A. PAT. APP. NO.(S) series code/serial no See Attached Appendix (4 pages) 5. Name & Address of Party to Concerning Document Shou Pillsbury Winthrop LLP Intellectual Property Group	(S). OTHERS ON ADDITIONAL 1st INVENTOR if not in item 1 Whom Correspondence Id be Mailed:	B. PATENT NO(S) See Attached Appendix 6. NUMBER INVO APPLNS 112 + 7. AMOUNT OF FEI ABOVE TOTAL x	LVED: PATS <u>34</u> = TOTAL = E DUE: (Code 8021) \$40 = \$5840	<u>if not in item 1</u> <u>146</u>
4.5 APPL. NO.(S) OR PAT NO. A. PAT. APP. NO.(S) Series code/serial no See Attached Appendix (4 pages) 5. Name & Address of Party to Concerning Document Should Pillsbury Winthrop LLP Intellectual Property Group P.O. Box 10500 McLean, VA 2 5.5ATTY DKT:	(S). OTHERS ON ADDITIONAL 1st INVENTOR if not in item 1 Whom Correspondence Id be Mailed:	B. PATENT NO(S) See Attached Appendix 6. NUMBER INVO APPLNS 112 + 7. AMOUNT OF FEI ABOVE TOTAL x 8. PLEASE CHARGE NUMBER: 03-3975	LVED: PATS <u>34</u> = TOTAL = E DUE: (Code 8021) \$40 = \$5840	if not in item 1 146 OUNT
4.5 APPL. NO.(S) OR PAT NO. A. PAT. APP. NO.(S) series code/serial no See Attached Appendix (4 pages) 5. Name & Address of Party to Concerning Document Shou Pillsbury Winthrop LLP Intellectual Property Group P.O. Box 10500 McLean, VA 2 5.5ATTY DKT: P 037003-0000051	(S). OTHERS ON ADDITIONAL 1st INVENTOR if not in item 1 Whom Correspondence Id be Mailed:	B. PATENT NO(S) See Attached Appendix 6. NUMBER INVO APPLNS 112 + 7. AMOUNT OF FEI ABOVE TOTAL x 8. PLEASE CHARGE NUMBER: 03-3975 UNDER ORDER NO	LVED: PATS 34 = TOTAL = E DUE: (Code 8021) \$40 = \$5840 TO OUR DEPOSIT ACCO	16 not in item 1 146 OUNT 0000051
4.5 APPL. NO.(S) OR PAT NO. A. PAT. APP. NO.(S) series code/serial no See Attached Appendix (4 pages) 5. Name & Address of Party to Concerning Document Shou Pillsbury Winthrop LLP Intellectual Property Group P.O. Box 10500 McLean, VA 2 5.5ATTY DKT: P 037003-0000051 MATTER NO.	(S). OTHERS ON ADDITIONAL 1st INVENTOR if not in item 1 Whom Correspondence Id be Mailed: 2102 CLIENT REF.	B. PATENT NO(S) See Attached Appendix 6. NUMBER INVO APPLNS 112 + 7. AMOUNT OF FEI ABOVE TOTAL x 8. PLEASE CHARGE NUMBER: 03-3975 UNDER ORDER NO dup. sheet not required	LVED: PATS 34 = TOTAL = E DUE: (Code 8021) \$40 = \$5840 TO OUR DEPOSIT ACCO 0 037003 CLIENT NO.	146 0UNT 0000051 MATTER NO.
4.5 APPL. NO.(S) OR PAT NO. A. PAT. APP. NO.(S) series code/serial no See Attached Appendix (4 pages) 5. Name & Address of Party to Concerning Document Shou Pillsbury Winthrop LLP Intellectual Property Group P.O. Box 10500 McLean, VA 2 5.5ATTY DKT: P 037003-0000051 MATTER NO. 9. To the best of my knowledge	(S). OTHERS ON ADDITIONAL 1st INVENTOR if not in item 1 Whom Correspondence Id be Mailed:	B. PATENT NO(S) See Attached Appendix 6. NUMBER INVO APPLNS 112 + 7. AMOUNT OF FEI ABOVE TOTAL x 8. PLEASE CHARGE NUMBER: 03-3975 UNDER ORDER NO dup. sheet not required	LVED: PATS 34 = TOTAL = E DUE: (Code 8021) \$40 = \$5840 TO OUR DEPOSIT ACCO 0 037003 CLIENT NO.	146 0UNT 0000051 MATTER NO.
4.5 APPL. NO.(S) OR PAT NO. A. PAT. APP. NO.(S) series code/serial no See Attached Appendix (4 pages) 5. Name & Address of Party to Concerning Document Shou Pillsbury Winthrop LLP Intellectual Property Group P.O. Box 10500 McLean, VA 2 5.5ATTY DKT: P 037003-0000051 MATTER NO.	(S). OTHERS ON ADDITIONAL 1st INVENTOR if not in item 1 Whom Correspondence Id be Mailed: 2102 CLIENT REF.	B. PATENT NO(S) See Attached Appendix 6. NUMBER INVO APPLNS 112 + 7. AMOUNT OF FEI ABOVE TOTAL x 8. PLEASE CHARGE NUMBER: 03-3975 UNDER ORDER NO dup. sheet not required	LVED: PATS 34 = TOTAL = E DUE: (Code 8021) \$40 = \$5840 TO OUR DEPOSIT ACCO 0 037003 CLIENT NO.	146 0UNT 0000051 MATTER NO.
4.5 APPL. NO.(S) OR PAT NO. A. PAT. APP. NO.(S) series code/serial no See Attached Appendix (4 pages) 5. Name & Address of Party to Concerning Document Shou Pillsbury Winthrop LLP Intellectual Property Group P.O. Box 10500 McLean, VA 2 5.5ATTY DKT: P 037003-0000051 MATTER NO. 9. To the best of my knowledge	(S). OTHERS ON ADDITIONAL 1st INVENTOR if not in item 1 Whom Correspondence Id be Mailed: 2102 CLIENT REF.	B. PATENT NO(S) See Attached Appendix 6. NUMBER INVO APPLNS 112 + 7. AMOUNT OF FE ABOVE TOTAL x 8. PLEASE CHARGE NUMBER: 03-3975 UNDER ORDER NO dup. sheet not required ation is true and correct	LVED: PATS 34 = TOTAL = E DUE: (Code 8021) \$40 = \$5840 TO OUR DEPOSIT ACCO 037003 CLIENT NO. t and any attached copy	146 0UNT 0000051 MATTER NO.
4.5 APPL. NO.(S) OR PAT NO. A. PAT. APP. NO.(S) series code/serial no See Attached Appendix (4 pages) 5. Name & Address of Party to Concerning Document Shou Pillsbury Winthrop LLP Intellectual Property Group P.O. Box 10500 McLean, VA 2 5.5ATTY DKT: P 037003-0000051 MATTER NO. 9. To the best of my knowledge	(S). OTHERS ON ADDITIONAL 1st INVENTOR if not in item 1 Whom Correspondence Id be Mailed: 2102 CLIENT REF.	B. PATENT NO(S) See Attached Appendix 6. NUMBER INVO APPLNS 112 + 7. AMOUNT OF FEI ABOVE TOTAL x 8. PLEASE CHARGE NUMBER: 03-3975 UNDER ORDER NO dup, sheet not required ation is true and correct	LVED: PATS 34 = TOTAL = EDUE: (Code 8021) \$40 = \$5840 TO OUR DEPOSIT ACCO 0 037003 CLIENT NO. t and any attached copy pages including this	146 OUNT 0000051 MATTER NO. is a true copy of
4.5 APPL. NO.(S) OR PAT NO. A. PAT. APP. NO.(S) series code/serial no See Attached Appendix (4 pages) 5. Name & Address of Party to Concerning Document Shou Pillsbury Winthrop LLP Intellectual Property Group P.O. Box 10500 McLean, VA 2 5.5ATTY DKT: P 037003-0000051 MATTER NO. 9. To the best of my knowledge	(S). OTHERS ON ADDITIONAL 1st INVENTOR if not in item 1 Whom Correspondence Id be Mailed: 2102 CLIENT REF.	B. PATENT NO(S) See Attached Appendix 6. NUMBER INVO APPLNS 112 + 7. AMOUNT OF FEI ABOVE TOTAL x 8. PLEASE CHARGE NUMBER: 03-3975 UNDER ORDER NO dup. sheet not required ation is true and correct	LVED: PATS 34 = TOTAL = EDUE: (Code 8021) \$40 = \$5840 TO OUR DEPOSIT ACCO 0 037003 CLIENT NO. t and any attached copy pages including this nents and document	146 0UNT 0000051 MATTER NO.
4.5 APPL. NO.(S) OR PAT NO. A. PAT. APP. NO.(S) series code/serial no See Attached Appendix (4 pages) 5. Name & Address of Party to Concerning Document Shou Pillsbury Winthrop LLP Intellectual Property Group P.O. Box 10500 McLean, VA 2 5.5ATTY DKT: P 037003-0000051 MATTER NO. 9. To the best of my knowledge the original document.	(S). OTHERS ON ADDITIONAL 1st INVENTOR if not in item 1 Whom Correspondence Id be Mailed: 2102 CLIENT REF. e and belief, the foregoing information	B. PATENT NO(S) See Attached Appendix 6. NUMBER INVO APPLNS 112 + 7. AMOUNT OF FEI ABOVE TOTAL x 8. PLEASE CHARGE NUMBER: 03-3975 UNDER ORDER NO dup, sheet not required ation is true and correct	LVED: PATS 34 = TOTAL = EDUE: (Code 8021) \$40 = \$5840 TO OUR DEPOSIT ACCO 0 037003 CLIENT NO. t and any attached copy pages including this nents and document	146 OUNT 0000051 MATTER NO. is a true copy of
4.5 APPL. NO.(S) OR PAT NO. A. PAT. APP. NO.(S) series code/serial no See Attached Appendix (4 pages) 5. Name & Address of Party to Concerning Document Shou Pillsbury Winthrop LLP Intellectual Property Group P.O. Box 10500 McLean, VA 2 5.5ATTY DKT: P 037003-0000051 MATTER NO. 9. To the best of my knowledge the original document. Signature	(S). OTHERS ON ADDITIONAL 1st INVENTOR if not in item 1 Whom Correspondence Id be Mailed: 2102 CLIENT REF. e and belief, the foregoing information of the correspondence in the correspondence i	B. PATENT NO(S) See Attached Appendix 6. NUMBER INVO APPLNS 112 + 7. AMOUNT OF FEI ABOVE TOTAL x 8. PLEASE CHARGE NUMBER: 03-3975 UNDER ORDER NO dup. sheet not required ation is true and correct	LVED: PATS 34 = TOTAL = EDUE: (Code 8021) \$40 = \$5840 TO OUR DEPOSIT ACCO 0 037003 CLIENT NO. t and any attached copy pages including this nents and document	146 OUNT 0000051 MATTER NO. is a true copy of
4.5 APPL. NO.(S) OR PAT NO. A. PAT. APP. NO.(S) series code/serial no See Attached Appendix (4 pages) 5. Name & Address of Party to Concerning Document Should Pillsbury Winthrop LLP Intellectual Property Group P.O. Box 10500 McLean, VA 2 5.5 ATTY DKT: P 037003-0000051 MATTER NO. 9. To the best of my knowledge the original document. Signature Attorney: Thomas A. Cawley	(S). OTHERS ON ADDITIONAL 1st INVENTOR if not in item 1 Whom Correspondence Id be Mailed: 2102 CLIENT REF. e and belief, the foregoing information of the correspondence in the correspondence i	B. PATENT NO(S) See Attached Appendix 6. NUMBER INVO APPLNS 112 + 7. AMOUNT OF FE ABOVE TOTAL x 8. PLEASE CHARGE NUMBER: 03-3975 UNDER ORDER NO dup. sheet not required ation is true and correct 10. Total number of cover sheet, attachm (do not file dup. Cov	LVED: PATS 34 = TOTAL = EDUE: (Code 8021) \$40 = \$5840 TO OUR DEPOSIT ACCO 0 037003 CLIENT NO. t and any attached copy pages including this nents and document er sheet)	146 OUNT 0000051 MATTER NO. is a true copy of
4.5 APPL. NO.(S) OR PAT NO. A. PAT. APP. NO.(S) series code/serial no See Attached Appendix (4 pages) 5. Name & Address of Party to Concerning Document Shou Pillsbury Winthrop LLP Intellectual Property Group P.O. Box 10500 McLean, VA 2 5.5ATTY DKT: P 037003-0000051 MATTER NO. 9. To the best of my knowledge the original document. Signature	(S). OTHERS ON ADDITIONAL 1st INVENTOR if not in item 1 Whom Correspondence Id be Mailed: 2102 CLIENT REF. e and belief, the foregoing information of the correspondence in the correspondence i	B. PATENT NO(S) See Attached Appendix 6. NUMBER INVO APPLNS 112 + 7. AMOUNT OF FEI ABOVE TOTAL x 8. PLEASE CHARGE NUMBER: 03-3975 UNDER ORDER NO dup. sheet not required ation is true and correct	LVED: PATS 34 = TOTAL = EDUE: (Code 8021) \$40 = \$5840 TO OUR DEPOSIT ACCO 0 037003 CLIENT NO. t and any attached copy pages including this ments and document er sheet)	146 OUNT 0000051 MATTER NO. is a true copy of

Patents

Matter No.	Serial No.	Filing Date	Patent No.	Issue Date
281199	07/680,808	March 12, 1991	5,270,202	December 14, 1993
275979	07/919,787	July 24, 1992	5,585,103	December 17, 1996
275402	08/147,696	November 3, 1993	5,648,267	July 15, 1997
275715	08/379,072	January 25, 1995	5,658,570	August 19, 1997
275655	08/478,039	June 7, 1995	5,681,722	October 28, 1997
275656	08/481,869	June 7, 1995	5,693,780	December 2, 1997
275658	08/472,311	June 7, 1995	5,695,770	December 9, 1997
275799	08/351,001	December 7, 1994	5,709,860	January 20, 1998
275403	08/484,334	June 7, 1995	5,733,779	March 31, 1998
275657	08/476,349	June 7, 1995	5,750,105	May 12, 1998
275973	08/476,237	June 7, 1995	5,756,096	May 26, 1998
275757	08/488,376	June 7, 1995	5,811,524	September 22, 1998
275843	08/819,866	March 14, 1997	5,830,698	November 3, 1998
275676	08/634,223	April 18, 1996	5,840,298	November 24, 1998
275679	08/634,224	April 18, 1996	5,866,125	February 2, 1999
275677	08/634,400	April 18, 1996	5,939,068	August 17, 1999
275678	08/635,878	April 18, 1996	5,955,364	September 21, 1999
275844	09/023,715	February 13, 1998	5,998,144	December 7, 1999
275832	08/554,840	November 7, 1995	6,001,358	December 14, 1999
275404	09/013,092	January 26, 1998	6,017,733	January 25, 2000
275942	08/487,550	June 7, 1995	6,113,898	September 5, 2000
275680	08/523,894	September 6, 1995	6,136,310	October 24, 2000
275732	09/280,999	March 30, 1999	6,159,730	December 12, 2000
275801	09/024,220	February 17, 1998	6,197,311	March 6, 2001
275407	09/261,207	March 3, 1999	6,207,858	March 27, 2001
276461	08/449,728	May 24, 1995	6,270,769	August 7, 2001
275831	09/259,347	March 1, 1999	6,300,143	October 9, 2001
275759	09/335,697	June 18, 1999	6,413,771	July 2, 2002
275807	09/343,485	June 30, 1999	6,413,777	July 2, 2002
275833	08/925,339	September 8, 1997	6,440,418	August 27, 2002
275983	09/625,856	July 26, 2000	6,451,284	September 17, 2002
275683	09/332,595	June 14, 1999	6,506,383	January 14, 2003
275716	09/383,916	August 26, 1999	6,709,654	March 23, 2004
275802	09/740,003	December 20, 2000	6,733,763	May 11, 2004

Applications

	-74.7	1	1
Matter No.	Serial No.	Filing Date	Status
281198	07/431,426	November 3, 1989	ABANDONED
275969	07/735,064	July 25, 1991	ABANDONED
275978	07/735,069	July 25, 1991	ABANDONED
275970	07/856,281	March 23, 1992	ABANDONED
275971	07/912,292	July 10, 1992	ABANDONED
275730	07/977,691	November 13, 1992	ABANDONED
275800	08/476,674	June 7, 1995	ABANDONED
275943	08/746,361	November 8, 1996	ABANDONED
275999	08/933,359	September 18, 1997	ABANDONED
275974	09/082,472	May 21, 1998	ABANDONED
277092	09/149,479	September 8, 1998	ABANDONED
275733	09/615,796	July 13, 2000	ABANDONED
280601	09/834,933	April 16, 2001	ABANDONED
280614	09/850,165	May 8, 2001	ABANDONED
280631	09/877,065	June 11, 2001	ABANDONED
282604	09/971,631	October 9, 2001	ABANDONED
277093	60/057,831	September 8, 1997	LAPSED
275531	60/109,607	November 23, 1998	LAPSED
275820	60/134,848	May 19, 1999	LAPSED
275980	60/148,288	August 11, 1999	LAPSED
275842	60/185,390	February 28, 2000	LAPSED
276451	60/189,050	March 14, 2000	LAPSED
275675	60/193,467	March 31, 2000	LAPSED
275477	60/199,365	April 25, 2000	LAPSED
275545	60/209,584	June 6, 2000	LAPSED
275474	60/210,451	June 9, 2000	LAPSED
275490	60/212,668	June 20, 2000	LAPSED
275819	60/213,252	June 22, 2000	LAPSED
275471	60/217,706	July 12, 2000	LAPSED
275435	60/233,607	September 18, 2000	LAPSED
275544	60/233,625	September 18, 2000	LAPSED
275473	60/241,022	October 20, 2000	LAPSED
276519	60/257,147	December 22, 2000	LAPSED
277109	60/264,318	January 29, 2001	LAPSED
280060	60/280,139	April 2, 2001	LAPSED
280616	60/300,063	June 25, 2001	LAPSED
277149	60/303,813	July 10, 2001	LAPSED
282445	60/331,187	November 9, 2001	LAPSED
279155	60/331,481	November 16, 2001	LAPSED
280678	60/341,858	December 21, 2001	LAPSED
280677	60/341,860	December 21, 2001	LAPSED
280703-	60/357,140	February 19, 2002-	LAPSED
280692	60/367,727	March 28, 2002	LAPSED
280750	60/381,328	May 20, 2002	LAPSED

Matter No.	Serial No.	Filing Date	Status
			LAPSED
280757	60/386,746	June 10, 2002	LAPSED
280759	60/386,747	June 10, 2002	
280761	60/386,748	June 10, 2002	LAPSED
280760	60/386,759	June 10, 2002	LAPSED
280724	60/390,191	June 21, 2002	LAPSED
280763	60/396,082	July 17, 2002	LAPSED
280767	60/396,141	July 17, 2002	LAPSED
280764	60/396,255	July 17, 2002	LAPSED
280758	60/400,687	August 5, 2002	LAPSED
280772	60/405,318	August 23, 2002	LAPSED
280773	60/405,319	August 23, 2002	LAPSED
280765	60/410,506	September 13, 2002	LAPSED
291922	60/427,564	November 20, 2002	LAPSED
291923	60/428,274	November 22, 2002	LAPSED
291918	60/452,928	March 10, 2003	LAPSED
277113	09/238,741	January 28, 1999	PENDING
275818	09/259,337	March 1, 1999	PENDING
275984	09/259,338	March 1, 1999	PENDING
275478	09/435,992	November 8, 1999	PENDING
275532	09/447,594	November 23, 1999	PENDING
275681	09/576,424	May 22, 2000	PENDING
275543	09/612,914	July 10, 2000	PENDING
280721	09/628,186	July 28, 2000	PENDING
275726	09/635,929	August 10, 2000	PENDING
276603	09/758,173	January 12, 2001	PENDING
276658	09/772,938	January 31, 2001	PENDING
277869	09/791,551	February 26, 2001	PENDING
277931	09/798,525	February 21, 2001	PENDING
279190	09/805,217	March 14, 2001	PENDING
280062	09/822,672	April 2, 2001	PENDING
280609	09/840,872	April 25, 2001	PENDING
280618	09/853,580	May 14, 2001	PENDING
280617	09/853,581	May 14, 2001	PENDING
280623	09/855,717	May 16, 2001	PENDING
280624	09/856,534	September 4, 2001	PENDING
280632	09/874,141	June 6, 2001	PENDING
280637	09/883,962	June 20, 2001	PENDING
280657	09/954,274	September 18, 2001	PENDING
280728	09/982,849	October 22, 2001	PENDING
280731	09/985,646	November 5, 2001	PENDING
280732	09/986,174	November 7, 2001	PENDING
280727	10/058,069	January 29, 2002	PENDING
280743	10/058,120	January 29, 2002	PENDING
280705	10/073,138	February 13, 2002	PENDING
280745	10/096,963	March 14, 2002	PENDING

9543775553

Matter No.	Serial No.	Filing Date	Status
280747	10/109,853	April 1, 2002	PENDING
280748	10/113,929	April 2, 2002	PENDING
280749	10/171,680	June 17, 2002	PENDING
280752	10/171,681	June 17, 2002	PENDING
	10/191,052	July 10, 2002	PENDING
291568	10/195,426	July 16, 2002	PENDING
280766	10/193,423	August 5, 2002	PENDING
280771	10/241,832	September 12, 2002	PENDING
291806	10/241,836	September 12, 2002	PENDING
291807	10/291,532	November 12, 2002	PENDING
291872		November 18, 2002	PENDING
291921	10/295,823	December 23, 2002	PENDING
301015	10/326,924	February 19, 2003	PENDING
301988	10/367,978	rebruary 19, 2003	PENDING
302468	10/384,356	March 10, 2003	PENDING
305940	10/661,086	September 12, 2003	PENDING
307430	10/743,398	December 23, 2003	PENDING
307368	10/743,739	December 24, 2003	
276000	60/148,287	August 11, 1999	PENDING
304387	60/479,910	June 20, 2003	PENDING
306302	60/510,552	October 14, 2003	PENDING
306645	10/703,669	November 10, 2003	PENDING
308678	10/796,158	March 10, 2004	PENDING
310260	10/871,261	June 21, 2004	PENDING

30443426_1.xis

This Page is Inserted by IFW Indexing and Scanning Operations and is not part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

□ BLACK BORDERS
□ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
□ FADED TEXT OR DRAWING
□ BLURRED OR ILLEGIBLE TEXT OR DRAWING
□ SKEWED/SLANTED IMAGES
□ COLOR OR BLACK AND WHITE PHOTOGRAPHS
□ GRAY SCALE DOCUMENTS
□ LINES OR MARKS ON ORIGINAL DOCUMENT
□ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY

IMAGES ARE BEST AVAILABLE COPY.

OTHER:

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.